Gestational diabetes: telemedicine could help, but the evidence remains weak

What the researchers assessed

This systematic review brings together trials of telemedicine interventions for managing gestational diabetes. The researchers examined blood glucose control, weight gain during pregnancy, and several maternal and neonatal health outcomes.

The abstract provided does not detail the tools used, the frequency of contact, the duration of interventions, or the care received in each comparison group. It therefore cannot identify a specific remote monitoring model to favor.

Favorable results, but not for every outcome

The pooled estimates suggest reductions in fasting blood glucose, blood glucose two hours after a meal, and gestational weight gain. The review also reports lower risks of cesarean delivery, emergency cesarean delivery, macrosomia, neonatal hypoglycemia, and neonatal respiratory distress.

However, no statistically significant difference was found for glycated hemoglobin, preterm birth, or neonatal intensive care admission. This does not establish equivalence between the care approaches.

The abstract does not provide the absolute risks of complications. It is therefore impossible to infer how many women or newborns would actually benefit from remote monitoring.

Why the average is not enough

For both blood glucose measures and weight gain, the results show very high heterogeneity that the analyses do not explain. In other words, the trials do not all tell the same story.

The prediction intervals include no effect for these three outcomes. Even though the pooled average effect is statistically significant, a new study conducted in a different setting might therefore find no benefit.

The authors rate the certainty of the evidence as low to very low for all outcomes assessed. The number of trials alone does not make up for these uncertainties.

A possible addition, not a replacement

Telemedicine could complement care when travel or distance makes in-person monitoring difficult. However, this review does not establish that it would be superior in every setting, or that it could entirely replace standard prenatal care.

The practical question remains which tools, which interactions with healthcare professionals, and which populations account for the observed benefits. The authors call for better-standardized trials and longer follow-up to check whether maternal and neonatal benefits persist.

What we can take away

The signal is encouraging for supplementing gestational diabetes monitoring. It remains too uncertain to justify replacing usual prenatal care with entirely remote monitoring.